Please ensure Javascript is enabled for purposes of website accessibility

Why BioXcel Therapeutics Stock Popped Today

By Prosper Junior Bakiny - Feb 1, 2021 at 4:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A Wall Street analyst has high hopes for the company.

What happened

Shares of BioXcel Therapeutics (BTAI 2.49%) jumped by as much as 14.4% on Monday -- and finished the trading session up 11.7% -- thanks to a Wall Street analyst making a bullish case for the biopharmaceutical company.

So what

UBS analyst Colin Bristow initiated coverage of BioXcel Therapeutics' stock with a buy rating and a $99 price target. The company's shares are worth $51.72 apiece after today's rally. Why does Bristow see such huge potential upside for BioXcel Therapeutics'? The answer lies with the company's leading pipeline candidate, sublingual thin film BXCL501. In a phase 3 clinical trial, BXCL501 was shown to be effective in treating acute agitation in patients with schizophrenia and bipolar disorder.

Hand drawing upward pointing graph.

Image source: Getty Images.

Although BioXcel Therapeutics currently has no products on the market, Bristow thinks that its current stock price is supported by BXCL501's opportunity in treating patients with those two psychological disorders. However, the analyst sees an even bigger upside for the stock in another market. BXCL501 is also being investigated as a treatment for acute agitation in patients with dementia, an opportunity that exceeds the schizophrenia and bipolar disorder markets combined.

Now what

It is always wise to take analyst recommendations with a grain of salt. But for what it's worth, Bristow is onto something, at least in my view. BXCL501's potential does seem very enticing. What's more, BioXcel Therapeutics currently has a market cap of only $1.26 billion, and that's after the company's shares gained 211.5% over the past 12 months. In other words, it is definitely worth keeping an eye on this healthcare stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioXcel Therapeutics, Inc. Stock Quote
BioXcel Therapeutics, Inc.
BTAI
$13.57 (2.49%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.